(866 days)
The Sensititre® YeastOne™ MIC Susceptibility plate is an in vitro diagnostic product for determining the clinical susceptibility of Candida species. This 510(k) is for this MIC only panel, the antifungal agents at concentrations listed as follows: Antifungal Agent Dilution Range Fluconazole 0.125 - 256 5-Flucytosine 0.03 - 64 Itraconazole 0.008 - 16 Organisms with indications for testing include non-fastidious yeast isolates of Candida species.
Not Found
This document is a 510(k) premarket notification for the Sensititre® YestOne™ MIC Susceptibility Plate. It describes the device, its intended use, and the FDA's "substantially equivalent" determination. However, it does not contain the detailed acceptance criteria and study results typically found in a clinical study report or a more comprehensive summary of safety and effectiveness.
Therefore, requested information cannot be fully provided from the given input.
Here's an explanation of why and what information can be extracted:
- No detailed study information: The provided text is a summary of the FDA's decision to clear the device, not the underlying studies themselves. It confirms the device exists and is intended for susceptibility testing of Candida species against specific antifungal agents.
- "Substantially Equivalent": The core of a 510(k) is demonstrating "substantial equivalence" to a legally marketed predicate device, not necessarily proving efficacy against pre-defined acceptance criteria in a detailed clinical study in the same way a PMA would. While performance data is submitted for a 510(k), the specifics of that data (acceptance criteria, sample sizes for test/training, ground truth methods, expert qualifications, etc.) are usually in a separate, more comprehensive document that is not included here.
Information that can be extracted or inferred:
- Device Name: Sensititre® YestOne™ MIC Susceptibility Plate
- Regulation Number: 866.1640
- Regulation Name: Susceptibility Test Panel
- Product Code: NGZ
- Intended Use: Determining the clinical susceptibility of Candida species to Fluconazole, 5-Flucytosine, and Itraconazole.
- Antifungal Agents and Dilution Ranges (relevant for the device's function):
- Fluconazole: 0.125 - 256
- 5-Flucytosine: 0.03 - 64
- Itraconazole: 0.008 - 16
What cannot be answered from this document:
- Table of acceptance criteria and reported device performance: This document states the device is "substantially equivalent" but does not show the specific performance results (e.g., essential agreement, categorical agreement, very major errors, major errors, minor errors) that would typically be presented against defined acceptance criteria.
- Sample sizes (test/training sets): Not mentioned.
- Data provenance: Not mentioned. Studies are implied but not described.
- Number/qualifications of experts for ground truth: Not mentioned.
- Adjudication method for test set: Not mentioned.
- MRMC comparative effectiveness study: Not mentioned and typically not applicable for this type of IVD device (which measures a characteristic, not an interpretation by a human reader).
- Standalone (algorithm only) performance: Not applicable as this is a physical susceptibility plate, not an AI algorithm.
- Type of ground truth used: For antimicrobial susceptibility testing, the "ground truth" (or reference method) is typically a standardized susceptibility test method (e.g., Clinical and Laboratory Standards Institute - CLSI reference broth microdilution). However, this document does not explicitly state which gold standard or reference method was used for comparison in the studies that underpin the 510(k).
- Sample size for training set: Not mentioned.
- How ground truth for training set was established: Not mentioned.
To answer your request thoroughly, you would need access to the actual "Summary of Safety and Effectiveness" (SSE) or the full 510(k) submission, which would detail the studies conducted to demonstrate substantial equivalence, including performance data and the methods used.
{0}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/0/Picture/1 description: The image is a seal for the Department of Health & Human Services - USA. The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is a stylized image of an eagle with its wings spread.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
OCT - 92001
Ms. Cindy Knapp Trek Diagnostic Systems 29299 Clemens Rd. Suite 1-K Westlake Ohio 44145
Re: K991810/S1
Trade/Device Name: Sensititre® YestOne™ MIC Susceptibility Plate Regulation Number: 866,1640 Regulation Name: Susceptibility Test Panel Regulatory Class: Class II Product Code: NGZ Dated: October 11, 2000 Received: September 19, 2001
Dear Ms. Knapp:
.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{1}------------------------------------------------
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
1991810 510(k) Number (if known):
Device Name: Susceptibility Test Panel
Indications For Use:
The Sensititre® YeastOne™ MIC Susceptibility plate is an in vitro diagnostic product for determining the clinical susceptibility of Candida species.
This 510(k) is for this MIC only panel, the antifungal agents at concentrations listed as follows:
| Antifungal Agent | Dilution Range |
|---|---|
| Fluconazole | 0.125 - 256 |
| 5-Flucytosine | 0.03 - 64 |
| Itraconazole | 0.008 - 16 |
Organisms with indications for testing include non-fastidious yeast isolates of Candida species.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Steven Butman
(Division Sign-Off) Division of Clinical Laboratory Devices
510(k) Number K991810
Prescription Use
OR
Over-The-Counter Use__________________________________________________________________________________________________________________________________________________________
§ 866.1640 Antimicrobial susceptibility test powder.
(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).